Agios Pharmaceuticals ROE 2024

Agios Pharmaceuticals Aktienanalyse

What does Agios Pharmaceuticals do?

Agios Pharmaceuticals Inc. is a US biopharmaceutical company specializing in the development of treatment options for rare genetic disorders and cancer. The company was founded in 2008 by David Schenkein, Lewis Cantley, and Tak Mak and is headquartered in Cambridge, Massachusetts. The history of Agios Pharmaceuticals Inc. began with the discovery of IDH1 mutations, which are frequently found in many types of cancer. The founders of Agios recognized the significance of this discovery and laid the foundation for the development of drugs targeting this mutation. Agios' business model is to develop innovative therapeutics for diseases that are often neglected by other companies. The company focuses on researching enzymes that play important roles in genetic disorders and cancer processes. Agios collaborates closely with other companies and research institutions to quickly translate its research findings into clinical research and subsequent patient treatment. Additionally, the company has established itself as a pioneer in the application of artificial intelligence in drug development in recent years. Agios divides its portfolio into two main areas: oncology and rare genetic disorders. In oncology, the company utilizes targeted therapies based on a deep understanding of the underlying cancer biology. Therapeutic approaches include enzyme inhibitors, immunotherapies, and cell therapies. Agios has several promising candidates in clinical development in this area, including Idhifa for the treatment of acute myeloid leukemia, as well as Ivosidenib and Ag-120, both used to treat brain tumors. In the field of rare genetic disorders, Agios specializes in a group of enzyme defects known as citric acid cycle disorders. Agios is the only provider of drugs targeting these enzymes. The company recently received approval for Tibsovo for the treatment of acute myeloid leukemia in the United States. Agios aims to continuously expand its pipeline of therapeutics to meet the unmet need for treatments for rare diseases and cancer. The company has an extensive research pipeline, with several drugs in preclinical and clinical development. Agios works closely with other companies and research institutions to quickly translate its research findings into clinical development and subsequent patient treatment. Overall, Agios Pharmaceuticals has made impressive strides in recent years and has established itself as a key player in the biopharmaceutical industry. The company specializes in developing innovative therapies for rare genetic disorders and cancer and collaborates closely with other companies and research institutions. With its extensive research pipeline and the application of artificial intelligence, Agios is well-positioned to contribute to the development of new therapeutic options in the future. Agios Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Agios Pharmaceuticals's Return on Equity (ROE)

Agios Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Agios Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Agios Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Agios Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Agios Pharmaceuticals stock

What is the ROE (Return on Equity) of Agios Pharmaceuticals this year?

The ROE of Agios Pharmaceuticals this year is -0.43 undefined.

How has the Return on Equity (ROE) of Agios Pharmaceuticals developed compared to the previous year?

The ROE of Agios Pharmaceuticals has increased by 106.17% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Agios Pharmaceuticals?

A high ROE indicates that Agios Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Agios Pharmaceuticals?

A low ROE can indicate that Agios Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Agios Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of Agios Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Agios Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Agios Pharmaceuticals?

Some factors that can influence Agios Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Agios Pharmaceuticals pay?

Over the past 12 months, Agios Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agios Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Agios Pharmaceuticals?

The current dividend yield of Agios Pharmaceuticals is .

When does Agios Pharmaceuticals pay dividends?

Agios Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Agios Pharmaceuticals?

Agios Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Agios Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Agios Pharmaceuticals located?

Agios Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Agios Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Agios Pharmaceuticals from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Agios Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Agios Pharmaceuticals in the year 2023?

In the year 2023, Agios Pharmaceuticals distributed 0 USD as dividends.

In which currency does Agios Pharmaceuticals pay out the dividend?

The dividends of Agios Pharmaceuticals are distributed in USD.